102 Chapter 5 Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding 5, Additional File 1: 10-11 (b) Describe any methods used to examine subgroups and interactions 5, Additional File 1: 10-11 (c) Explain how missing data were addressed 5, Additional File 1: 10, 14 (d) If applicable, explain how loss to follow-up was addressed NA (e) Describe any sensitivity analyses NA Results Participants 13 (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed 5-6, Figure 1 (b) Give reasons for non-participation at each stage 6, Figure 1 (c) Consider use of a flow diagram Figure1 Descriptive data 14 * (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders 5-6, Additional File 1: 13, 15, 18-19 (b) Indicate number of participants with missing data for each variable of interest 5-6, Additional File 1: 14 (c) Summarise follow-up time (eg, average and total amount) 5-6, Additional File 1: 22 Outcome data 15 Report numbers of outcome events or summary measures over time 6-9 Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included 6-9, Additional File 1: 16-17 (b) Report category boundaries when continuous variables were categorized 6-9 (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period NA Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses 8-9, Additional File 1: 16-19, 26-29
RkJQdWJsaXNoZXIy MTk4NDMw